Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses
C Ohyama, T Kojima, T Kondo, Y Naya, T Inoue… - International Journal of …, 2019 - Springer
Background Nivolumab has demonstrated antitumor activity and manageable safety in the
single-arm, phase II CheckMate 275 study in patients with unresectable locally advanced or …
single-arm, phase II CheckMate 275 study in patients with unresectable locally advanced or …
Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update from CheckMate 275.
AO Siefker-Radtke, AD Baron, A Necchi, ER Plimack… - 2019 - ascopubs.org
4524 Background: In the open-label, single-arm, phase 2 CheckMate 275 trial, objective
response rate (ORR) for patients (pts) with metastatic urothelial carcinoma (mUC) with …
response rate (ORR) for patients (pts) with metastatic urothelial carcinoma (mUC) with …
Abstract CT178: Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update and association between …
P Sharma, A Baron, A Necchi, ER Plimack, SK Pal… - Cancer Research, 2018 - AACR
Introduction: Nivolumab monotherapy has already shown efficacy and safety in the open-
label, single-arm, phase II CheckMate 275 trial (objective response rate [ORR], 19.6%) …
label, single-arm, phase II CheckMate 275 trial (objective response rate [ORR], 19.6%) …
Nivolumab in patients with advanced platinum-resistant urothelial carcinoma: efficacy, safety, and biomarker analyses with extended follow-up from CheckMate 275
MD Galsky, A Saci, PM Szabo, GC Han… - Clinical Cancer …, 2020 - AACR
Purpose: We report efficacy and safety with extended follow-up, and exploratory biomarker
analyses from the phase II CheckMate 275 trial to identify biomarkers of response to …
analyses from the phase II CheckMate 275 trial to identify biomarkers of response to …
Nivolumab monotherapy in metastatic urothelial carcinoma: Longer-term efficacy and safety results from the CheckMate 032 study.
P Sharma, MK Callahan, P Bono, JW Kim… - 2018 - ascopubs.org
414 Background: Nivolumab has shown efficacy and acceptable safety in 2 open-label,
multicenter studies (CheckMate 032 and 275) and is approved for patients (pts) with …
multicenter studies (CheckMate 032 and 275) and is approved for patients (pts) with …
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
P Sharma, MK Callahan, P Bono, J Kim… - The lancet …, 2016 - thelancet.com
Background Few effective treatments exist for patients with advanced urothelial carcinoma
that has progressed after platinum-based chemotherapy. We assessed the activity and …
that has progressed after platinum-based chemotherapy. We assessed the activity and …
Efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer (mUC) who have received prior treatment: Results from the phase II …
MD Galsky, M Retz, AO Siefker-Radtke… - Annals of …, 2016 - annalsofoncology.org
Background Chemotherapy for platinum-resistant advanced mUC yields poor objective
response rates (ORR) and overall survival (OS). Nivolumab (NIVO) recently showed …
response rates (ORR) and overall survival (OS). Nivolumab (NIVO) recently showed …
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
P Sharma, M Retz, A Siefker-Radtke, A Baron… - The lancet …, 2017 - thelancet.com
Background Patients with metastatic urothelial carcinoma have a dismal prognosis and few
treatment options after first-line chemotherapy. Responses to second-line treatment are …
treatment options after first-line chemotherapy. Responses to second-line treatment are …
Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma: CheckMate 032 nivolumab 1 mg/kg plus ipilimumab 3 mg/kg expansion …
P Sharma, A Siefker-Radtke, F de Braud… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE CheckMate 032 is an open-label, multicohort study that includes patients with
unresectable locally advanced or metastatic urothelial carcinoma (mUC) treated with …
unresectable locally advanced or metastatic urothelial carcinoma (mUC) treated with …
[HTML][HTML] Nivolumab plus gemcitabine–cisplatin in advanced urothelial carcinoma
MS Van Der Heijden, G Sonpavde… - … England Journal of …, 2023 - Mass Medical Soc
Background No new agent has improved overall survival in patients with unresectable or
metastatic urothelial carcinoma when added to first-line cisplatin-based chemotherapy …
metastatic urothelial carcinoma when added to first-line cisplatin-based chemotherapy …